[Evaluation of effectiveness of Catalin eyedrops in patients with presenile and senile cataract].
OBJECTIVE
Evaluation of effectiveness of Catalin eye drops in inhibition of cataract or eventual influence on regression of actually present opacities.


METHODS
72 patients in age over 40 years with initial cortical cataract and visual acuity better than 0.5 were evaluated. 35 patients were treated with anticataracous drug Catalin, and 37 received placebo. All patients were evaluated with a slit-lamp and modern equipment EAS-1000 (Nidek) before starting research and after 3, 6, 12, 18 and 24 months of treatment.


RESULTS
Catalin-eye drops in patients with cortical cataract showed its effectiveness in inhibition of lens opacification and its progression especially in group of patients in age up to 59 years. The increase of lens opacification in this group was only 1.425% (Catalin), and in older group (placebo) even 9.228%. Appropriate, raising effect of the drug can be observed after 18 months of treatment. Catalin-eye drops did not cause any complications during the study.


CONCLUSIONS
1. Catalin-eye drops used in patients with senile and presenile cortical cataract is effective drug in inhibiting lens opacification. 2. The function of the drug is more obvious in group of younger patients (up to 59 years of age) in comparison with older ones. 3. Appropriate, raising effect of the drug can be observed after 18 months of treatment. 4. Catalin-eye drops is well tolerated by the patients even after prolonged application.
Kociecki
Jarosław
J
Kliniki Okulistycznej Akademii Medycznej w Poznaniu.
Załecki
Krzysztof
K
Wasiewicz-Rager
J
J
Pecold
Krystyna
K
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002386:Cataract / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D010078:Oxazines / Q000008:administration & dosage / Q000627:therapeutic use*
D009883:Ophthalmic Solutions; D010078:Oxazines; C004580:pirenoxine